Professional technology integration to support the entire R&D process

In the field of cancer immunotherapy, a new wave of drug R&D is surging toward next-generation immune checkpoints, following in the footsteps of CTLA-4 and PD-1. Among these, ICOS (Inducible T-cell Costimulator, also known as CD278) has captured global pharmaceutical attention due to its unique dual immunomodulatory functions. As a pivotal molecule in co-stimulatory signaling pathways, ICOS acts as both an "accelerator" for enhancing anti-tumor immunity and a potential "accomplice" in tumor immune evasion. Achieving precise modulation of this target is the cornerstone of successful drug development. Leveraging cutting-edge technology, Reqbio has developed a comprehensive series of ICOS (CD278) Cell Models covering the ICOS/ICOSL pathway, designed to provide global researchers with highly efficient and reliable tools for early-stage drug screening.

I. ICOS/ICOSL: An Immune Checkpoint with a "Double Identity"

ICOS is the third member of the CD28 receptor family and is primarily expressed on the surface of activated T cells, belonging to the immunoglobulin superfamily. Its ligand, ICOSL (also known as B7-H2 or CD275), is found on antigen-presenting cells (APCs) or certain tumor cells. The interaction between ICOS and ICOSL transmits a potent co-stimulatory signal.

The effects of this signaling are both complex and subtle:

Anti-tumor Roles: In effector T cells (such as Th1 and cytotoxic T lymphocytes/CTLs), ICOS signaling promotes activation, proliferation, and effector functions, directly intensifying the killing of cancer cells.

Pro-tumor Roles: Conversely, this signal can also enhance the immunosuppressive functions of regulatory T cells (Tregs) or promote Th2 cell subsets, thereby facilitating tumor immune evasion.

It is precisely this coexistence of "activation" and "suppression" that makes the ICOS pathway an incredibly attractive yet challenging target for drug R&D. Determining how to selectively amplify anti-tumor effects while blocking pro-tumor activity through rational drug design is currently a major research hotspot in the industry.

II. The ICOS Signaling Pathway: From Molecular Structure to Cellular Function

As a type I transmembrane glycoprotein, ICOS contains a relatively short intracellular domain (approximately 35 amino acids), yet it is capable of transmitting critical co-stimulatory signals. Unlike the CD28 pathway, ICOS co-stimulation results in reduced IL-2 production while strongly inducing cytokines such as IL-4, IL-10, and IL-21, thereby playing an essential regulatory role during the early stages of T-cell differentiation.

In Tfh cell differentiation:

ICOS is highly expressed on PD-1^hi CXCR5^hi Tfh cells and is crucial for promoting germinal center responses and the generation of high-affinity antibodies.

In Tregs:

ICOS⁺ regulatory T cells (Tregs) exhibit enhanced suppressive activity, and their proportion in peripheral blood has been associated with autoimmune diseases.

In effector T cells:

ICOS signaling also promotes the differentiation and functional activity of Th1, Th2, and Th17 subsets.

Ⅲ.Drug Development Strategies Targeting ICOS: Agonism or Antagonism?

Given the dual roles of ICOS, global development of anti-ICOS antibodies is currently divided into two strategic camps:

ICOS Agonists: These aim to activate effector T cells (particularly ICOS$^{hi}$ T cells) to bolster anti-tumor immunity. Pre-clinical studies have demonstrated that ICOS agonists can exert a synergistic effect with anti-CTLA-4 therapy. The theoretical basis for this combination lies in the significant expansion of tumor-infiltrating ICOS$^{hi}$ T cells following CTLA-4 blockade.

ICOS Antagonists: These are designed to block ICOS signaling, thereby inhibiting the accumulation and suppressive function of Tregs and dismantling the immunosuppressive microenvironment. This strategy is particularly applicable to tumor types with high Treg infiltration, such as certain hematologic malignancies.

To date, no ICOS-targeted drugs have received regulatory approval worldwide; however, several candidates have entered clinical phases. Their potential as monotherapies or in combination with PD-1/CTLA-4 antibodies is highly anticipated by the industry.

Ⅳ.Global Progress of ICOS-Targeted Drug Candidates (Selected)

Looking ahead at R&D trends, beyond monoclonal antibodies, bispecific antibodies (e.g., ICOS x PD-1) and combination therapies are emerging as the new strategic pivot, aimed at achieving more precise modulation of the immune response.

Ⅴ. Accelerate ICOS Drug Discovery with Reqbio’s One-Stop Cell Model Solutions

Addressing the complexities of ICOS-targeted development, Reqbio has launched a suite of highly validated ICOS (CD278) Cell Models. These are designed to provide comprehensive technical support for the development of agonistic and antagonistic antibodies, as well as bispecific candidates.

Catalog:

Data:

Core Product Advantages： 

High Stability and Specificity: Ensures consistent and reproducible experimental results.

Well-Defined Functionality: Reporter gene cell lines are rigorously validated to respond sensitively to ICOS signaling.

Flexible and Versatile: A full range of options is available, from overexpressing cells to functional reporter cell lines, suitable for different stages of research and development.

IV. Conclusion

With the deepening understanding of ICOS biology and the optimization of combination therapy strategies, this target holds great promise for the development of breakthrough therapeutics in the near future. Renkun Biotech remains committed to providing high-quality biological reagents and cell models to empower innovative drug discovery worldwide. Whether you are developing novel ICOS antibodies or exploring combination therapies, our tools are designed to accelerate your research from the lab to the clinic.

Contact us today to access detailed technical specifications or request a trial of our ICOS cell models!